2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

201. Granulocytes, Monocytes, and Macrophages: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Genetic Disorders, Immunology, Autoimmune Disorders, Neutropenia, White Blood Cell Disorders, Infectious Diseases, Viral, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

2972 Anti-CD38 therapy (daratumumab) for the treatment of autoimmune neutropenia

David Brian Sykes, MD, PhD, Rebecca K. Leaf, MD2
1 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
2 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States

CASE PRESENTATION. A 23-year-old nurse was referred to hematology clinic due to pronounced neutropenia (absolute neutrophil count (ANC) = 100/uL) and a dental infection. She noted symptoms of fatigue, leg pain in her hips and thighs, and night sweats for several weeks, but no documented fevers. She took no medications and had no significant medical history, childhood illness, or recurrent or unexplained infections.

WORKUP & DIAGNOSIS. The remainder of her complete blood count (CBC) and differential were normal. An extensive laboratory work-up was unrevealing including testing for hematinic deficiencies, EBV, CMV, rheumatologic disorders, and paroxysmal nocturnal hemoglobinuria. An ultrasound of the abdomen demonstrated a spleen of 13 cm (normal <12). She underwent a bone marrow biopsy that demonstrated a slightly hypercellular marrow with increased myelopoiesis and no evidence of hematologic malignancy.

A CBC performed 6 years prior demonstrated an ANC of 1800/uL. A panel of gene testing for congenital neutropenias (23 genes) was negative. Anti-neutrophil antibody testing revealed the presence of a weak anti-neutrophil antibody, supporting a diagnosis of an acquired autoimmune neutropenia (AiN).

PATIENT COURSE: The patient continued to have pronounced fatigue, leg pain, and sweats. Unfortunately, she also began to suffer recurrent episodes of cellulitis, folliculitis, and one episode of bacteremia that required inpatient hospitalizations. These episodes would occur every 2 to 3 months and were often triggered by small skin abrasions sustained while shaving.

UNSUCCESSFUL TREATMENT TRIALS: Given the frequency of infections and admissions, we undertook a series of treatment trials to address her AiN.

Treatment with short-acting G-CSF (300 mcg three times weekly and then 300 mcg daily) led to minimal improvement in ANC and was associated with worsening bone pain and sweats.

Treatment with intravenous immunoglobulin (IVIG, 0.5 grams/kg) monthly x 3 months also failed to raise the ANC and ultimately resulted in hospitalization for aseptic meningitis.

The patient received a course of rituximab (375 mg/m2) weekly for 4 weeks in combination with mycophenolate (500 mg) twice daily without improvement in her ANC or symptoms.

She received a single dose of GM-CSF (250 mcg) that lead to worsening bony pain, myalgias, fevers, and chills.

She received a course of fostamatinib (100 mg twice daily and then 150 mg twice daily) for 12 weeks without improvement in her ANC or symptoms.

SUCCESSFUL USE OF DARATUMUMAB: Five years after her original presentation, the patient’s ANC remained approximately 400/mL and she continued to experience fatigue, leg pains, and sweats. Given the refractory nature of her disease, she was treated with the anti-CD38 monoclonal antibody daratumumab (16 mg/kg intravenously weekly for 4 weeks). Her ANC increased to an average of approximately 1000/ul, accompanied by marked improvement in her symptoms.

Over the next 6 months, the patient’s ANC gradually declined to approximately ~450/ul, with recurrence of her constitutional symptoms. She then received daratumumab-hyaluronidase (1800 mg subcutaneously weekly for 4 weeks). Her ANC improved to an average of ~1300/mL, again accompanied by marked symptomatic improvement.

She has since received a third course of daratumumab-hyaluronidase with improvement in her ANC from ~500/ul to ~1400/ul and resolution of her symptoms.

Since initiating daratumumab therapy, she has required neither antibiotic treatment nor hospitalization.

DISCUSSION: AiN is a heterogenous condition arising from immune-mediated destruction of circulating neutrophils. Although many patients remain asymptomatic despite markedly reduced ANCs, others experience constitutional symptoms, recurrent infections, and impaired quality of life. GCSF remains the first-line treatment; however, its administration can be burdensome and may not produce a sustained response. As illustrated by this case, alternative therapies are largely empiric and often have limited efficacy. We describe a patient with refractory AiN who experienced reproducible hematologic and clinical responses to anti-CD38–directed therapy. Importantly, the improvement in her ANC was accompanied by substantial improvement in her symptoms and quality of life.

David Brian Sykes, MD, PhD: X4 Pharma - Consultancy (Includes expert testimony)